Jonathan C Fox - Net Worth and Insider Trading
Jonathan C Fox Net Worth
The estimated net worth of Jonathan C Fox is at least $101 Million dollars as of 2024-05-21. Jonathan C Fox is the Chief Medical Officer of MyoKardia Inc and owns about 239,190 shares of MyoKardia Inc (MYOK) stock worth over $54 Million. Jonathan C Fox is the See Remarks of Eidos Therapeutics Inc and owns about 380,967 shares of Eidos Therapeutics Inc (EIDX) stock worth over $47 Million. Jonathan C Fox is also the Director of Edgewise Therapeutics Inc and owns about 10,857 shares of Edgewise Therapeutics Inc (EWTX) stock worth over $193,580. Details can be seen in Jonathan C Fox's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jonathan C Fox has not made any transactions after 2023-12-26 and currently still holds the listed stock(s).
Transaction Summary of Jonathan C Fox
Jonathan C Fox Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jonathan C Fox owns 3 companies in total, including Eidos Therapeutics Inc (EIDX) , MyoKardia Inc (MYOK) , and Edgewise Therapeutics Inc (EWTX) .
Click here to see the complete history of Jonathan C Fox’s form 4 insider trades.
Insider Ownership Summary of Jonathan C Fox
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| EIDX | Eidos Therapeutics Inc | 2020-09-17 | See Remarks |
| MYOK | MyoKardia Inc | 2016-04-29 | Chief Medical Officer |
| EWTX | Edgewise Therapeutics Inc | 2023-12-26 | director |
Jonathan C Fox Latest Holdings Summary
Jonathan C Fox currently owns a total of 3 stocks. Among these stocks, Jonathan C Fox owns 239,190 shares of MyoKardia Inc (MYOK) as of November 3, 2015, with a value of $54 Million and a weighting of 53.5%. Jonathan C Fox owns 380,967 shares of Eidos Therapeutics Inc (EIDX) as of September 17, 2020, with a value of $47 Million and a weighting of 46.3%. Jonathan C Fox also owns 10,857 shares of Edgewise Therapeutics Inc (EWTX) as of December 26, 2023, with a value of $193,580 and a weighting of 0.19%.
Latest Holdings of Jonathan C Fox
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MYOK | MyoKardia Inc | 2015-11-03 | 239,190 | 224.91 | 53,796,223 |
| EIDX | Eidos Therapeutics Inc | 2020-09-17 | 380,967 | 122.21 | 46,557,977 |
| EWTX | Edgewise Therapeutics Inc | 2023-12-26 | 10,857 | 17.83 | 193,580 |
Holding Weightings of Jonathan C Fox
Jonathan C Fox Form 4 Trading Tracker
According to the SEC Form 4 filings, Jonathan C Fox has made a total of 0 transactions in MyoKardia Inc (MYOK) over the past 5 years. The most-recent trade in MyoKardia Inc is the acquisition of 3,000 shares on November 3, 2015, which cost Jonathan C Fox around $30,000.
According to the SEC Form 4 filings, Jonathan C Fox has made a total of 18 transactions in Eidos Therapeutics Inc (EIDX) over the past 5 years, including 0 buys and 18 sells. The most-recent trade in Eidos Therapeutics Inc is the sale of 5,767 shares on September 17, 2020, which brought Jonathan C Fox around $289,273.
According to the SEC Form 4 filings, Jonathan C Fox has made a total of 1 transactions in Edgewise Therapeutics Inc (EWTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Edgewise Therapeutics Inc is the acquisition of 10,857 shares on December 26, 2023, which cost Jonathan C Fox around $100,970.
Insider Trading History of Jonathan C Fox
- 1
Jonathan C Fox Trading Performance
GuruFocus tracks the stock performance after each of Jonathan C Fox's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jonathan C Fox is 31.55%. GuruFocus also compares Jonathan C Fox's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jonathan C Fox within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jonathan C Fox's insider trading performs compared to the benchmark.
Performance of Jonathan C Fox
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 48.59 | | | | | |
| Relative Return to S&P 500(%) | 48.8 | | | | | |
Jonathan C Fox Ownership Network
Jonathan C Fox Owned Company Details
What does Eidos Therapeutics Inc do?
Who are the key executives at Eidos Therapeutics Inc?
Jonathan C Fox is the See Remarks of Eidos Therapeutics Inc. Other key executives at Eidos Therapeutics Inc include director & Chief Scientific Officer Uma Sinha , Senior Vice President & Finance Franco Valle , and Chief Business Officer Cameron Turtle .
Eidos Therapeutics Inc (EIDX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Eidos Therapeutics Inc (EIDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eidos Therapeutics Inc (EIDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Eidos Therapeutics Inc (EIDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eidos Therapeutics Inc Insider Transactions
Jonathan C Fox Mailing Address
Above is the net worth, insider trading, and ownership report for Jonathan C Fox. You might contact Jonathan C Fox via mailing address: C/o Myokardia, Inc., 333 Allerton Avenue, South San Francisco Ca 94080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
